The Impact of COVID-19 on the Health Care Utilization of Inflammatory Bowel Disease

NCT04387279 | Unknown

• 1 other identifier: 2020-04-070
• Study Type: observational
• Target: 800
• Locations: 1 country
• Sites: 1

Brief Summary

The rapid spread of COVID-19 is expected to have a significant impact on medicine as well as all sectors worldwide. In particular, inflammatory bowel disease (IBD) is a chronic immune disease in which remission and activation are repeated and must be treated consistently throughout life. In addition, patients with IBD may be vulnerable to various infectious diseases due to the immuno-compromised state due to the use of immuno-suppressants or biological agents. During a pandemic, patients with IBD may postpone hospital visits due to concerns about infection with COVID-19, and if they cannot continue drug treatment, there is a concern about the flare up IBD disease activity. Therefore, in this study, we would like to investigate the current status of hospital utilization of IBD patients in Daegu, the epidemic area of COVID-19, and to investigate the effect of patient perception of COVID-19 on hospital ultilization.

Conditions

COVID-19; Perception, Self; Facilities and Services Utilization

Outcome Measures

Primary Outcomes (1)

• Patient's perception of COVID-19 and medical use patterns

  Correlation between patient's perception of COVID-19 and medical use patterns during the pandemic period

  1day

Secondary Outcomes (1)

• Exacerbation of symptoms

  1day

Study Arms (1)

Inflammatory bowel disease

Patients with inflammatory bowel disease who live in COVID-19 hyperemic area

Other: Interview

Interventions

Interview OTHER

Surveys on medical use patterns and patient's perceptions about COVID-19

Inflammatory bowel disease

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study population will comprise the sample of all patients with inflammatory bowel disease, living in the Daegu city

You may qualify if:

• Patients with inflammatory growth disease, those who agreed to participate in this study

You may not qualify if:

• Those who are unable to understand or answer the questionnaire
• Those who declined to participate in this study

Sponsors & Collaborators

• Keimyung University Dongsan Medical Center: lead
• Yeungnam University College of Medicine: collaborator

Study Sites (1)

KeimyungUniversity

Daegu, Jung-gu, 700-712, South Korea

RECRUITING

MeSH Terms

Conditions

COVID-19

Interventions

Interviews as Topic

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• Yoojin Lee, M.D.

  Keimyung University Dongsan Medical Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Yoojin Lee, M.D.

CONTACT

82-53-258-7739; doctorlyj@naver.com

Kyeong Ok Kim, Ph.D.

CONTACT

kokim@yu.ac.kr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: May 12, 2020
• First Posted: May 13, 2020
• Study Start: April 24, 2020
• Primary Completion: March 30, 2021
• Study Completion: March 30, 2021
• Last Updated: May 13, 2020

Record last verified: 2020-05

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)